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In vivo testing of novel vaccine 
prototypes against Actinobacillus 
pleuropneumoniae
Fabio Antenucci1, Cyrielle Fougeroux2, Alannah Deeney3, Cathrine Ørskov4, Andrew Rycroft3, 
Peter Johannes Holst2 and Anders Miki Bojesen1* 
Abstract 
Actinobacillus pleuropneumoniae (A. pleuropneumoniae) is a Gram-negative bacterium that represents the main 
cause of porcine pleuropneumonia in pigs, causing significant economic losses to the livestock industry worldwide. 
A. pleuropneumoniae, as the majority of Gram-negative bacteria, excrete vesicles from its outer membrane (OM), 
accordingly defined as outer membrane vesicles (OMVs). Thanks to their antigenic similarity to the OM, OMVs have 
emerged as a promising tool in vaccinology. In this study we describe the in vivo testing of several vaccine prototypes 
for the prevention of infection by all known A. pleuropneumoniae serotypes. Previously identified vaccine candidates, 
the recombinant proteins ApfA and VacJ, administered individually or in various combinations with the OMVs, were 
employed as vaccination strategies. Our data show that the addition of the OMVs in the vaccine formulations signifi-
cantly increased the specific IgG titer against both ApfA and VacJ in the immunized animals, confirming the previ-
ously postulated potential of the OMVs as adjuvant. Unfortunately, the antibody response raised did not translate into 
an effective protection against A. pleuropneumoniae infection, as none of the immunized groups following challenge 
showed a significantly lower degree of lesions than the controls. Interestingly, quite the opposite was true, as the 
animals with the highest IgG titers were also the ones bearing the most extensive lesions in their lungs. These results 
shed new light on A. pleuropneumoniae pathogenicity, suggesting that antibody-mediated cytotoxicity from the host 
immune response may play a central role in the development of the lesions typically associated with A. pleuropneu-
moniae infections.
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Actinobacillus pleuropneumoniae (A. pleuropneumo-
niae) is a Gram-negative bacterium responsible for a 
serious respiratory disease affecting pigs and a cause of 
large economic losses in the pig industry [1, 2]. A. pleu-
ropneumoniae is transmitted from pig to pig by aerosols 
or direct contact and causes clinical signs such as vom-
iting, diarrhea, respiratory distress and bloody discharge 
from the mouth and nose, which may be lethal [3]. A 
total of 16 different A. pleuropneumoniae serotypes have 
been reported worldwide, classified according to cap-
sular antigens [4, 5]. Several serotypes contain strains 
that can cause severe symptoms, which makes it chal-
lenging to develop a broadly protective vaccine. Cur-
rently available vaccines against App can be divided in 
two categories: (i) vaccines based on inactivated whole-
cell bacterins; (ii) vaccines based on Apx toxins, a set of 
pore-forming cytolysins (Apx I–IV) playing a central role 
in App pathogenesis [3, 6]. Bacterin-based vaccines have 
been shown to offer limited protection against infections 
by strains other than the ones used for vaccination [7, 8]. 
While vaccines based on inactivated Apx toxins (toxoids) 
are effective in reducing the morbidity associated with 
infection [9–12] yet unable to prevent colonisation of the 
lungs, their use pose a potential threat inducing infec-
tion by asymptomatic carriers [7, 11, 13]. Thus, it would 
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be highly desirable to develop a novel vaccine offering 
protection against App colonisation and morbidity in a 
cross-serotype manner.
The poor specificity of the detection methods for A. 
pleuropneumoniae and the rapid progression of the infec-
tion frequently prompt widespread application of antibi-
otic treatment on the mere suspicion of an infection [14]. 
This contributes to the overuse of antibiotics, which pro-
motes selection of resistant bacteria and may indirectly 
lead to the spread of antibiotic resistance genes through 
the food chain [15, 16]. Accordingly, an effective vaccine 
against A. pleuropneumoniae, which protects across the 
16 serovars is urgently needed.
The pathogenesis of porcine pleuropneumonia is com-
plex and currently divided in different stages: coloniza-
tion, resistance to clearance and damage to host tissues 
(direct and indirect) [3, 17, 18]. Colonization is usually 
the fist step in the establishment of a bacterial infection, 
and several A. pleuropneumoniae virulence factors have 
been shown to be involved in adhesion to the host tissues 
and expressed in vivo [19, 20]. A. pleuropneumoniae cells 
also show the ability to avoid clearance by both innate 
and adaptive immune responses thanks to mechanisms 
such as antiphagocytic activity and antibody degrada-
tion [3, 6, 21]. Finally, the lesions typically associated with 
porcine pleuropneumonia are mostly caused by a combi-
nation of toxins and proteases secreted by the pathogen 
and inflammatory mediators released by activated phago-
cytes [3, 22, 23].
As previously mentioned, cross-serotype prevention of 
porcine pleuropneumoniae remains elusive, and success-
ful control of the infection with vaccination may require 
more in-depth knowledge of the pathogenesis of the dis-
ease. It is thus important to clarify how the establishment 
of the infection affects the course of the disease and if, as 
suggested; acute lung damage developed in the first days 
is the defining features for the severity of the disease [24]. 
Moreover it would be informative to understand if the 
infection can be controlled on a systemic level or mostly 
on a local level, thus determining the most efficient route 
of immunization.
In this study we describe the adoption of three different 
vaccination strategies for the prevention of porcine pleu-
ropneumonia and lung colonization by A. pleuropneumo-
niae. Different strategies were selected in order to offer 
to the host immune system the widest possible range 
of immunogens and alternative administration routes. 
The first strategy involved the utilization of previously 
selected cross-serotype immunogens [25], expressed as 
recombinant proteins. Briefly, the conserved immuno-
gens were selected in silico on the basis of exposition 
and accessibility of the proteins on the bacterial outer 
membrane (OM), as well as gene conservation among 
serovars, as described in [25]. From these studies we 
selected the proteins Apfa and VacJ, a pilin and an OM 
lipoprotein, respectively, whose role in A. pleuropneumo-
niae virulence previously has been described [11, 26, 27]. 
The selection of ApfA and VacJ as immunogens offered 
the potential of targeting A. pleuropneumoniae cells 
adhesion, OM integrity and resistance to clearance by the 
host immune system.
The second strategy involved the utilization of the 
antigenic outer membrane vesicles (OMVs) [28]. OMVs 
possess a variety of biological functions, and most impor-
tantly usually exhibit an antigenic pattern similar to the 
one found on the bacterial OM [29, 30]. Accordingly, A. 
pleuropneumoniae OMVs have shown promising results 
in terms of immunogenicity, offering the prospect of pro-
viding a range of conserved antigens [31]. Furthermore, 
thanks to their non-live nature, OMVs can be employed 
in vaccine formulations without incurring in the usual 
risks associated with live vaccines [29]. Notably, both 
autologous and heterologous OMVs have been reported 
to function as an adjuvant for co-administered recombi-
nant antigens [32–34], but more recently some contro-
versy has emerged regarding the possibility of combining 
OMVs with other immunogens [35]. To verify the poten-
tial of OMVs as adjuvants, we decided to combine OMVs 
and recombinant proteins ApfA and VacJ as a third strat-
egy of immunization.
One of the technical challenges during an infection 
trial is to ensure the thoroughly and equivalent dis-
semination of infectious particles through the groups of 
animals. As previously mentioned, one of the main trans-
mission routes of A. pleuropneumoniae infections is by 
aerosol [36, 37]. To simulate as closely as possible natural 
transmission, we selected an aerosol chamber transmis-
sion model as dissemination procedure for our in  vivo 
challenge. This system is ideally suited for a respiratory 
pathogen such A. pleuropneumoniae, and has already 
been tested successfully in several studies [38–40].
Materials and methods
Animal model
A total of 55 10-kg piglets (Landrace-Yorkshire-Duroc 
crossbred) were purchased from a commercial breeder, 
which was part of the Danish Specific-Pathogen-Free 
(SPF) breeding system (code red), which is the highest 
health level in the system. Briefly, code red SPF herds 
are tested monthly for App clinical signs and by a serum 
sample ELISA aiming at serotypes 1–10 and 12, respec-
tively. Upon arrival the pigs were housed in the animal 
facilities at the Department of Veterinary and Animal 
Sciences, (Frederiksberg, Copenhagen, Denmark). Piglets 
were ear-tagged with a unique identification number and 
randomly distributed in four different rooms that could 
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be further separated in three smaller pens, after vaccina-
tion. Experiments were started after allowing the pigs to 
acclimatize for a week. Daily care was provided by ani-
mal caretakers blinded to treatment groups. Experiments 
were approved by the Danish national animal experi-
ments inspectorate (Dyreforsøgstilsynet), as stipulated in 
license number 2014-15-0201-00019. Pigs were checked 
for presence of A. pleuropneumoniae by plating nose 
swaps on MHF plates [Mueller–Hinton agar + 5% horse 
blood  +  20  mg/L ß-nicotinamide dinucleotide (NAD); 
BioMérieux], before initiation of the experiment.
Immunogen production
Recombinant proteins ApfA and VacJ, and OMVs were 
produced and isolated as described in [25]. Briefly, apfA 
and vacJ genes from A. pleuropneumoniae L20 (serotype 
5b) were cloned and expressed in competent Escherichia 
coli (E. coli) BL21 (DE3) cells, and the resulting ApfA and 
VacJ proteins isolated by size exclusion chromatography 
as described in [41]. OMVs were produced from A. pleu-
ropneumoniae MIDG2331 (serotype 8) cultures and iso-
lated by hydrostatic filtration, as described in [25].
Immunization
The immunization and challenge procedure is summa-
rized in Figure  1. After 1-week of acclimatization pigs 
were vaccinated intra-muscularly and intranasally either 
with OMVs, recombinant proteins or a combination of 
OMVs and recombinant proteins (Table  1). Intramus-
cular (IM) immunizations were done by injecting 1  mL 
of the vaccine into the muscle on the dorsal side of the 
neck. Intranasal (IN) immunizations were made with 
1 mL volume of the vaccine instilled in one of the nostrils 
with a plastic Pasteur pipette (Deltalab). Group 1 (con-
trol) was administered 1  mL phosphate buffered saline 
(PBS). Groups 2, 3, 5, 6 and 7 were vaccinated with 30 μg 
WEEK 0 
Arrival of the 
pigs 
WEEK 1 
1st
immunization 
WEEK 5 
2nd
immunization 
WEEK 9 
APP 
challenge 
WEEK 10 
necropsy 
Group 1 
4 pigs 
PBS (IM+IN) PBS (IM+IN) 
106 CFU/mL in 
aerosol chamber
Group 2 
4 pigs 
VacJ protein (IM+IN) 
(30µg/mL) 
VacJ protein (IM+IN) 
(30µg/mL) 
Group 3 
4 pigs 
ApfA protein (IM+IN) 
(30µg/mL) 
ApfA protein (IM+IN) 
(30µg/mL)
Group 4 
4 pigs 
OMVs (IM+IN) 
(1,62.1010vesicles) 
OMVs (IM+IN) 
(1,62.1010vesicles) 
Group 5 
4 pigs 
OMVs +ApfA protein (IM+IN) 
(1,62.1010vesicles) +(30µg/mL) 
OMVs +ApfA protein (IM+IN) 
(1,62.1010vesicles) +(30µg/mL) 
Group 6 
4 pigs 
OMVs +VacJ protein (IM+IN) 
(1,62.1010vesicles) +(30µg/mL) 
OMVs +VacJ protein (IM+IN) 
(1,62.1010vesicles) +(30µg/mL) 
Group 7 
5 pigs 
OMVs +VacJ  +ApfA protein (IM+IN) 
(1,62.1010vesicles +((30µg/mL) + (30µg/mL) 
OMVs +VacJ  +ApfA protein (IM+IN) 
(1,62.1010vesicles) +(30µg/mL) + (30µg/
mL) 
Figure 1 Immunization and challenge regimen. Immunizations were carried out intra-nasally with a Pasteur pipette and intra-muscularly 
by injection. Animals were immunized with either a single component or a combination of the following: 30 μg/mL protein (Apfa and/or VacJ), 
1.62 × 1010 vesicles/mL OMV. All animals were re-immunized (boosted) 4 weeks after the first immunization. Finally, all pigs were challenged 
8 weeks after the first immunization with live A. pleuropneumoniae HK361 via an aerosol chamber. A week after challenge, pigs were euthanized and 
subjected to necropsy.
Table 1 Immunization groups
Immunogen combinations and route of immunization are detailed for each group.
Group Number of pigs Vaccination Route of immunization
1 4 PBS IM + IN
2 4 VacJ protein IM + IN
3 4 ApfA protein IM + IN
4 4 A. pleuropneumoniae OMV IM + IN
5 4 A. pleuropneumoniae OMV + VacJ protein IM + IN
6 4 A. pleuropneumoniae OMV + ApfA protein IM + IN
7 5 A. pleuropneumoniae OMV + VacJ protein + ApfA protein IM + IN
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(per protein) of recombinant protein and groups 4–7 
were vaccinated with 1.62 × 1010 OMV. The OMV dos-
age was set not to exceed tolerable lipopolysaccharide 
levels. Groups from 1 to 7 were boosted 4 weeks after the 
first immunization with a similar vaccine and dose as the 
first vaccination. Blood was drawn using the vacutainer 
system with clot activator (Vacutainer) from the jugular 
vein on day 0, week 2, week 4, week 6 and week 8 after 
the first vaccination and later, on the day of the A. pleu-
ropneumoniae challenge, and three and 7 days post chal-
lenge, respectively.
Challenge
All pigs were challenged with live A. pleuropneumoniae 
HK361 cells [serotype 2; National Collection of Type 
Cultures (NCTC) 10976], 8  weeks after the first vac-
cination. A. pleuropneumoniae bacteria from an over-
night BHI agar culture were incubated in brain-heart 
infusion (BHI) media supplemented with 5  μg/mL 
NAD (Sigma Aldrich). When the optical  density600  nm 
 (OD600 nm) reached 1.5 [corresponding to approximately 
2.109 colony-forming units (CFU)/mL according to pilot 
experiments], the culture was diluted 1:2000 in 30 mL of 
HEPES saline (10 mM HEPES; 150 mM NaCl, 3 mM KCl, 
1  mM  CaCl2 and 1  mM  MgCl2) to obtain a concentra-
tion of  106 CFU/mL. The diluted solution  (10−1) was then 
administered as an aerosol using a NE-U17 OMRON 
Ultrasonic nebuliser (OMRON Healthcare) and an aero-
sol chamber where four to five pigs at a time were left for 
10  min in a A. pleuropneumoniae aerosol. Each cham-
ber session was ended by a period of five min venting, 
to allow clearing of aerosolised A. pleuropneumoniae 
by passing all air through a HEPA filter before releasing 
the pigs from the chamber. Pigs were challenged over 
2 days, and overall two batches of A. pleuropneumoniae 
were produced and each batch was used for two to three 
groups of four to five pigs. The initial (pre challenge) A. 
pleuropneumoniae solution  (10−1) and the leftover solu-
tion (post challenge) were plated and incubated on MHF 
plates in duplicates, for recollection and CFU counting 
the next day.
Animal welfare
Clinical signs of the animals were monitored every 3–4 h 
during the period between challenge and euthanasia. 
Animals showing signs of distress or a body tempera-
ture  >  40  °C were administered IM injections of butor-
phanol tartrate (Torbugesic, Zoetis), dosed according to 
weight and previous treatment.
Post‑mortem examination
Pigs were sacrificed 1  week after the A. pleuropneu-
moniae challenge; lungs were excised from the thorax. 
Samples from lesions and healthy areas of the lungs 
were excised and placed in 10% formalin for histological 
analysis. The pleura and macroscopic lesions of the lungs 
were assessed systematically using a previously reported 
scoring system (Figure 2) [42]. Briefly, each of the seven 
lobes of each lung was assigned a score [0–5] depend-
ing on the number and size of lesions. From that the 
total score of the whole lung was calculated. The statisti-
cal significance of the data was assessed using Ordinary 
One-way ANOVA, Brown–Forsythe, Bartlett’s (P  < 0.05) 
and Dunnett’s multiple comparisons (alpha = 0.05) tests. 
Correlation between data sets was assessed by Pearson 
r two-tailed test (alpha = 0.05). After scoring, each lung 
was weighed and added 1/1 (weight/vol) 0.9% sterile 
saline solution (Thermo Fisher Scientific) and blended to 
obtain a homogenized mixture, which was serially diluted 
tenfold between 1:10−1 and 1:10−7. 10  μL of each dilu-
tion was then plated on MHF plates in duplicates. After 
overnight (ON) incubation, CFU counts were adjusted 
Figure 2 Scheme and pictures from infected porcine lungs 
after A. pleuropneumoniae infection. 7 weeks after their first 
immunization, pigs were challenged with a concentration of  106 CFU/
mL of live A. pleuropneumoniae HK361 in an aerosol chamber. 1 week 
after challenge, pigs were euthanized, and lungs and thorax were 
examined. A Example of lungs and thorax after A. pleuropneumoniae 
infection. B Lungs were assessed for their lesion score and number of 
lesions according to this scheme. Each pair of lungs was assigned a 
score based on the number and size of the lesions.
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in order to reflect the total amount of bacteria contained 
per gram of lung (CFU/g).
Antibody titration
Sera were isolated from blood samples by allowing the 
samples to clot. Nunc Maxisorp flat-bottom 96-wells 
plates (Thermo Fisher Scientific) were coated with 2 μg/
mL ApfA or VacJ proteins, or 3.25 × 108 OMVs in PBS, 
respectively. Sera from animals in the same group were 
pooled and added to the wells in three-fold dilutions 
between 1:500 and 1:1 093 500 (ApfA, VacJ) or 1:1000 and 
1:2 187 000 (OMVs). Antibodies specifically recognizing 
ApfA, VacJ and OMVs were detected with horseradish 
peroxidase (HRP)-conjugated polyclonal rabbit anti-pig 
IgG (Thermo Fisher Scientific). Wells were revealed using 
TMB plus (Kem-En-Tec Diagnostics). Optical density 
was measured at 450 nm using an enzyme-linked immu-
nosorbent assay (ELISA) plate reader (VersaMax Molec-
ular Devices).
Results
Inocula analysis
Actinobacillus pleuropneumoniae CFU counts from the 
inocula are summarized in Table  2. No statistically dif-
ferent CFU count was found between different batches, 
groups or days of challenge resulting in an expected simi-
lar inhaled dose for all pigs.
Histopathological analysis of the lungs
Lesion scores of the lungs are shown in Figure 3. Affected 
lungs presented lesions from subacute to acute, with signs 
of multifocal necrosis, fibrinous exudation and purulent 
inflammation. In some cases the extensive fibrinous exu-
dation to the pleural surface had led to extensive adhesive 
pleuritis (Figure  4). Some of the most severely affected 
lungs were partially or completely collapsed, suggesting 
loss of function (Figure 4). Statistical analysis showed no 
significant difference between mean lesion scores and 
standard deviations of each individual group (Figure  3), 
indicating that none of the vaccine formulations admin-
istered were able to successfully prevent A. pleuropneu-
moniae associated colonization and lesions. Instead, 
statistical analysis by Pearson r two-tailed test showed a 
correlation between the number of A. pleuropneumoniae 
Table 2 Inocula analysis
Serial dilutions from the inocula before and after challenge were plated on MHF 
plates. CFU counts are expressed as CFU/mL.
Batch Administered 
to group
CFU/mL (pre‑chal‑
lenge)
CFU/mL (post‑
challenge)
1 1, 2, 3, 4 2 × 106 3.25 × 106
2 5, 6, 7 1.46 × 106 1.85 × 106
Figure 3 Lesion scores of the lungs. Lungs were scored for lesions 
as previously described [42]. Mean and standard deviation values 
are graphically reported in figure. Statistical analysis by Ordinary 
One-way ANOVA, Brown–Forsythe, Bartlett’s and Dunnett’s multiple 
comparisons tests showed no significant difference between 
mean scores and standard deviations of each individual group. 1: 
PBS; 2: VacJ; 3: ApfA; 4: OMVs; 5: VacJ + OMVs; 6: ApfA + OMVs; 7: 
VacJ + ApfA + OMVs.
Figure 4 Post-mortem examination. Examples of healthy (A) and 
affected lung tissue (B) after A. pleuropneumoniae infection. Extensive 
necrosis and purulent lesions are evident in (B). C Thoracic cavity of 
the animal whose lungs are portrayed in B. White arrows indicate 
areas where pleuritis caused the adhesion of the lungs to the thoracic 
cavity.
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CFU present in the lungs and lesion scores (P < 0.0001) 
(Figure  5), validating the pathological evaluation perfor
med.
Histological analysis of the lesions revealed intense 
lymphocytic infiltration, with loss of structural integ-
rity and occlusion of the alveoli (Figure 6). No difference 
could be observed between individual groups, with sec-
tions of the lungs similarly affected exhibiting compara-
ble histological characteristics.
Characterization of IgG response to the immunogens
IgG titers from pig sera are shown in Figure 7. The sera 
retrieved from animals belonging to the same group were 
pooled together for immunological analysis. As such, the 
serological data and the resulting conclusions presented 
in this study are to be considered representative of trends 
per group rather than per individual animal.
Immunization with ApfA and VacJ proteins alone 
did not produce an appreciable increase in specific IgG 
antibodies against the proteins (Figure  7), suggesting 
the ineffectiveness of immunizing with these proteins 
individually. Furthermore, immunization with ApfA 
induced an IgG response against VacJ in the sera of vac-
cinated animals, suggesting that ApfA may interfere 
with the development of immunity against co-admin-
istered immunogens, as reported before [43]. Interest-
ingly, the animals in the control group presented a rather 
high titer against VacJ after challenge, pointing to the 
in  vivo immunogenicity of this protein (Figure  7). As 
expected given their multi-antigenic nature, the overall 
antibody response to the OMVs was conspicuous in all 
groups, with the highest titers reached when the OMVs 
were administered alone (Figure  7). Administration 
in combination with either of the other immunogens 
decreased the response to the OMVs, particularly before 
challenge, increasing on the other hand the response to 
the other immunogens (Figure  7). This was especially 
true in the case of VacJ, were groups that received both 
VacJ and OMVs showed steadily increasing and over-
all high IgG titers, while groups that received only VacJ 
showed a decrease in titer, even after challenge (Figure 7). 
Furthermore, statistical analysis by Pearson r two-tailed 
test showed a positive correlation between IgG titers 
elicited against the ApfA and VacJ immunogens and 
lesion scores (ApfA P = 0.04; VacJ P = 0.03), suggesting 
a major negative role of the immune system in A. pleuro-
pneumoniae pathogenesis (Figure 8). No correlation was 
observed between IgG response to the OMVs and lesion 
scores.
Discussion
Effective prevention of A. pleuropneumoniae outbreaks 
has remained elusive for decades, with available vaccines 
unable to confer cross-serotype protection or prevent 
lung colonization by A. pleuropneumoniae cells [11, 13]. 
To date, the most effective strategy relies on targeting 
a family of toxins centrally involved in A. pleuropneu-
moniae pathogenesis, the RTX toxins [22, 23]. Vaccines 
containing RTX toxoids have been shown to effectively 
prevent the clinical manifestations of the infection [7]. 
Unfortunately, this approach comes short of stopping 
lung colonization, and animals immunized in this way 
have been showed to be possible A. pleuropneumoniae 
carriers [44]. For this reason we chose to use different 
combinations of OM proteins and OMVs as immuniza-
tion strategies, similarly in principle to how the widely 
used  Bexsero® vaccine against Neisseria meningitidis was 
conceived [45].
Our data showed that none of the immunization strate-
gies employed was able to successfully prevent A. pleuro-
pneumoniae colonization or the development of lesions 
associated with infection. This may be due to different 
reasons, and our data, together with previously published 
studies [11, 25, 35], suggest caution in dismissing the 
selected immunogens as simply ineffective for immuni-
zation. As already mentioned, A. pleuropneumoniae pos-
sess several resistance mechanisms that allow it to avoid 
clearance by the host immune system. Accordingly, it is 
possible that raising antibodies against valid OM anti-
genic targets may not be sufficient for the host immune 
system to clear the infection before the RTX toxins 
and other virulence factors start to be released. Once 
released, most of A. pleuropneumoniae toxins can target 
specifically lymphocytes, and thus kill a wide range of 
the cells involved in clearance [23]. If this is the case, we 
hypothesise that a combination of OM immunogens and 
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Figure 5 CFU/Lesion score correlation. The number of A. pleuro-
pneumoniae CFU retrieved from the lungs after euthanasia was plot-
ted against the corresponding lesion score for each individual animal. 
Statistical analysis by Pearson two-tailed r test showed a significant 
correlation between number of CFU and lesion score (P < 0.0001).
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RTX toxoids may represent a valid immunization strat-
egy for the prevention of both colonization and patho-
genesis by A. pleuropneumoniae.
Another possibility comes from the role played by 
the host immune system during A. pleuropneumoniae 
infections. A. pleuropneumoniae cells are able to induce 
the release of pro-inflammatory mediators by acti-
vated phagocytes during infection, leading to extensive 
cytotoxicity due to the production of oxygen radicals 
and proteases [3, 22, 23]. Here we described a correla-
tion between IgG titers against ApfA and VacJ immu-
nogens and lesion scores (Figure  8), suggesting that 
a different cytotoxic pathway may be involved in the 
development of the lesions associated with A. pleuro-
pneumoniae. This alternative pathway is known as anti-
body-dependent cell-mediated cytotoxicity (ADCC), 
and has been demonstrated to be involved in the patho-
genesis of several bacterial infections [46, 47]. Our data 
point to the involvement of ADCC in A. pleuropneumo-
niae infections, showing that the groups with the high-
est IgG titers were the ones that had the highest lesion 
scores (Figure  8). Furthermore, the histological analy-
sis of the lungs seemed to confirm a major role for the 
host immune system in the development of the lesions, 
Figure 6 Histological analysis of the lungs. Healthy and affected regions of the lungs were cut out and sectioned for histopathological analysis. 
Sections were stained using hematoxylin and eosin stain (H&E). Only selected representative sections are shown for each type of affected animal. 
A, B Sections of healthy regions of the lungs. Normal structure and cellular components of the lungs are visible. C, D Sections of affected regions of 
the lungs. Loss of structure and heavy lymphocytic infiltrates are readily appreciable.
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in which affected lungs were heavily infiltrated by lym-
phocytes and showing extensive fibrinous exudation 
on occasions (Figures  4  and 6). This hypothesis may 
also explain the high variability in lesion score observed 
between animals belonging to the same group, as the 
pathological outcome of an A. pleuropneumoniae infec-
tion could be much more dependent on the individually 
variable immune response than on infectious dose (ID). 
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Figure 7 IgG response to the immunogens. Sera from animals within each individual group were pooled together and analysed for IgG con-
centration against ApfA (A), VacJ (B) and OMVs (C). Data are reported as area under curve (AUC), calculated from ELISA titration curves. Three time 
points are shown: 0: first immunization; pre: second immunization; post: endpoint.
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Figure 8 IgG titer/lesion score correlation. Combined IgG titers for each animal group (1–7) against ApfA (A) and VacJ (B) were plotted against 
the average lesion score of each individual group. Pooled endpoint sera retrieved on the day of euthanasia (1 week after challenge) were used. 
Statistical analysis by Pearson two-tailed r test showed a significant correlation between average IgG titers and lesion scores (ApfA P = 0.04; VacJ 
P = 0.03).
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Although the role of ADCC in App pathogenicity has 
yet to be proven, it has been shown that a high serocon-
version rate towards the PalA protein produced by App 
is inversely correlated with protection level in animals 
immunised with this protein [48]. Notably, no correla-
tion was present between IgG response to the OMVs and 
lesion scores, likely due to the generalised high response 
in all animals to the LPS present in the OMVs. Indeed, if 
ADCC is effectively responsible for considerable damage 
in A. pleuropneumoniae infections; we could be forced to 
rethink our approach to both treatment and prevention, 
as raising IgG titers against A. pleuropneumoniae OM 
antigens may prove counterproductive. In this scenario, 
a combination of immunization by RTX toxoids and a 
desensitisation regime toward ADCC could achieve bet-
ter results and be instrumental in reducing antibiotic 
consumption.
As expected, immunization with the OMVs elicited a 
rather high IgG titer in the animals, exhibiting adjuvant 
properties when administered in combination with the 
other immunogens (Figure  7). This did not come as a 
surprise, as the adjuvant potential of the OMVs has been 
widely demonstrated in previous studies [29, 49, 50]. 
On the other hand, ApfA and VacJ elicited a rather low 
response when administered alone (Figure 7). Our results 
contrast with previous reports on ApfA, indicating both 
immunogenic and protective potential in  vivo [11, 26]. 
Interestingly, VacJ was found to elicit a consistently high 
IgG titer after challenge (Figure  7), suggesting that this 
protein may possess a relevant immunogenic potential 
in vivo.
Finally, our results show a general reliability of the chal-
lenge model used and the effectiveness of the aerosol 
chamber as a biologically relevant method to study the 
pathogenesis of A. pleuropneumoniae. OMV dosage dur-
ing immunization was effective in eliciting the maximum 
immune response within tolerable parameters of toxicity. 
All animals received approximately the same amount of 
A. pleuropneumoniae CFU during challenge and devel-
oped a subacute infection, while none of them needed to 
be euthanized before the planned endpoint due to criti-
cal clinical conditions. Moreover, the positive correlation 
between CFU in the lungs and lesion score shows the 
validity of the scoring system used.
In conclusion, our study provided new insight into A. 
pleuropneumoniae pathogenicity and the role played by 
host-derived cytotoxicity. The aerosol chamber repre-
sented a reliable and effective device for A. pleuropneu-
moniae challenge, ensuring that all animals were exposed 
to the same ID through the natural route of infection. On 
the other hand, the evident contrast between the over-
all technical reproducibility achieved and the high vari-
ability in lesion score within each group underlines the 
complexity of the A. pleuropneumoniae pathogenesis. 
To address this issue and provide a more solid statisti-
cal basis, larger groups of animals may be needed during 
similar A. pleuropneumoniae trials in the future.
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